FDA to require class-wide REMS for opioid drugs
This article was originally published in The Gold Sheet
Manufacturers of potent opioid drug products will soon be required to have a Risk Evaluation & Mitigation Strategy (REMS) in place to mitigate the potential risk of drug abuse. FDA announced on Feb. 11 that letters were sent to 16 manufacturers of 24 marketed products notifying them of the new requirement. The focus of the class-wide program will be on products that FDA says are most prone to abuse: extended-release tablets and transdermal patches, including fentanyl, methadone and oxycodone. There have been manufacturing problems related to some of these products, especially the fentanyl patches which have been found to have defective delivery systems with patches potentially leaking fentanyl gel (see "The Gold Sheet," Jan. 2009, p. 18)
You may also be interested in...
Fresenius Kabi must pay Eli Lilly €28m in damages after a French court of first instance found that the generics firm’s pemetrexed infringed intellectual property protecting the Alimta chemotherapy brand. The German firm has commented on possible next steps.
Japanese ophthalmic specialist picks up young private US firm and gains a small but broad set of marketed products.
Meeting to address opioid abuse crisis was also a trial of whether FDA could conduct important public business using online-only technology.